We are live on ! Find out more
LSC

Lyon Street Capital Portfolio holdings

AUM $67M
This Fund
S&P 500
This Quarter Est. Return
+21.27%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$300M
AUM Growth
+$40.5M
Cap. Flow
+$2.32M
Cap. Flow %
0.77%
Top 10 Hldgs %
46.35%
Holding
64
New
9
Increased
20
Reduced
13
Closed
11

Top Buys

Rank Stock Value
1
BFYT
Benefytt Technologies, Inc. Class A Common Stock
BFYT
+$11.5M
2
BEAT
BioTelemetry, Inc.
BEAT
+$10.5M
3
SBBP
Strongbridge Biopharma plc.
SBBP
+$6.19M
4
LGND icon
Ligand Pharmaceuticals
LGND
+$5.52M
5
NEOS
Neos Therapeutics, Inc
NEOS
+$5.36M

Top Sells

Rank Stock Value
1
STMP
Stamps.com, Inc.
STMP
+$5.42M
2
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$5.21M
3
HLF icon
Herbalife
HLF
+$5.05M
4
EHTH icon
eHealth
EHTH
+$4.59M
5
AXGN icon
Axogen
AXGN
+$4.14M

Sector Composition

Rank Sector Weight
1 Healthcare 33.34%
2 Technology 18.99%
3 Financials 14.84%
4 Communication Services 9.98%
5 Industrials 5.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BFYT
1
DELISTED
Benefytt Technologies, Inc. Class A Common Stock
BFYT
$36.3M 12.09%
1,453,484
+516,737
+55% +$11.5M
GTT
2
DELISTED
GTT Communications, Inc.
GTT
$15.6M 5.21%
332,486
+24,231
+8% +$924K
NTUS
3
DELISTED
Natus Medical Inc
NTUS
$13.1M 4.38%
343,645
+50,748
+17% +$2.03M
STML
4
DELISTED
Stemline Therapeutics, Inc.
STML
$12.9M 4.31%
829,090
+287,628
+53% +$3.85M
SVRA icon
5
Savara
SVRA
$1.13B
$11.6M 3.86%
779,554
+271,214
+53% +$3.11M
BEAT
6
DELISTED
BioTelemetry, Inc.
BEAT
$11.3M 3.78%
379,029
+363,677
+2,369% +$10.5M
MODN
7
DELISTED
MODEL N, INC.
MODN
$10.5M 3.5%
666,277
+89,492
+16% +$1.35M
SBBP
8
DELISTED
Strongbridge Biopharma plc.
SBBP
$10.2M 3.4%
1,406,095
+991,322
+239% +$6.19M
UPLD icon
9
Upland Software
UPLD
$12M
$9.47M 3.16%
43,738
+4,847
+12% +$1.06M
NEOS
10
DELISTED
Neos Therapeutics, Inc
NEOS
$7.99M 2.67%
783,583
+558,117
+248% +$5.36M
CARB
11
DELISTED
Carbonite Inc
CARB
$7.6M 2.54%
302,896
-48,811
-14% -$1.13M
NXRT
12
NexPoint Residential Trust
NXRT
$665M
$7.23M 2.41%
258,622
+8,635
+3% +$228K
IMMU
13
DELISTED
Immunomedics Inc
IMMU
$7.22M 2.41%
446,703
+296,703
+198% +$3.5M
ATSG
14
DELISTED
Air Transport Services Group
ATSG
$6.75M 2.25%
291,894
– –
LOPE icon
15
Grand Canyon Education
LOPE
$3.71B
$6.27M 2.09%
70,000
-18,826
-21% -$1.7M
TYL icon
16
Tyler Technologies
TYL
$12.2B
$6.14M 2.05%
34,687
– –
ICUI icon
17
ICU Medical
ICUI
$3.93B
$6.11M 2.04%
28,280
+9,556
+51% +$1.93M
HDP
18
DELISTED
Hortonworks, Inc.
HDP
$5.74M 1.91%
285,389
+10,605
+4% +$195K
FIVN icon
19
FIVE9
FIVN
$1.77B
$5.71M 1.9%
229,501
– –
ASMB icon
20
Assembly Biosciences
ASMB
$506M
$5.68M 1.89%
10,454
-2,000
-16% -$905K
LGND icon
21
Ligand Pharmaceuticals
LGND
$6.02B
$5.44M 1.82%
+63,729
New +$5.52M
WIRE
22
DELISTED
Encore Wire Corp
WIRE
$5.42M 1.81%
111,327
+35,625
+47% +$1.65M
CNCE
23
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$5.28M 1.76%
204,077
-258,987
-56% -$5.21M
CALD
24
DELISTED
Callidus Software, Inc.
CALD
$4.87M 1.62%
170,015
-42,741
-20% -$1.17M
CCS icon
25
Century Communities
CCS
$2B
$4.66M 1.55%
149,670
– –
1
2 3

Similar funds

DCM
Dockyard Capital Management Boston, Massachusetts $70.6M AUM
SCMU
Steadfast Capital Management (UK) London, United Kingdom $71.5M AUM
TLCM
Tiger Legatus Capital Management New York $62.4M AUM 24.33% 1-Year Est. Return
EA
Elm Advisors Burlingame, California $74.1M AUM 7.85% 1-Year Est. Return
A
Astrantus Limassol, Cyprus $59.4M AUM
AAI
Accomplice Associates II Boston, Massachusetts $57.8M AUM
EM
Endicott Management New York $81.7M AUM 36.01% 1-Year Est. Return
ALFA
Accel Leaders Fund Associates Palo Alto, California $51.5M AUM

Lyon Street Capital's Q4 2017 Portfolio in Review

As of Q4 2017, Lyon Street Capital held 64 positions worth $300M, up 16% from $259M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Lyon Street Capital's Q4 2017 filing shows 9 new, 20 increased, 13 reduced and 11 closed positions. Its largest new stake was Ligand Pharmaceuticals: 63,729 shares worth $5.44M. The largest sale was Stamps.com, Inc., an estimated $5.42M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 23% a quarter earlier, followed by Technology and Financials.

  • Lyon Street Capital's largest Q4 2017 buy was Ligand Pharmaceuticals: 63,729 shares worth $5.44M.
  • Lyon Street Capital added most to Benefytt Technologies, Inc. Class A Common Stock in Q4 2017, an estimated $11.5M increase.
  • Lyon Street Capital's biggest Q4 2017 reduction was Concert Pharmaceuticals, Inc., cutting an estimated $5.21M.
  • Lyon Street Capital fully exited Stamps.com, Inc. in Q4 2017, selling an estimated $5.42M.
  • Lyon Street Capital's ten largest holdings make up 46% of its $300M portfolio in Q4 2017.
  • Lyon Street Capital opened 9 new positions and closed 11 in Q4 2017.
  • Lyon Street Capital's portfolio value rose 16% quarter-over-quarter to $300M.

Based on Lyon Street Capital's 13F filing for Q4 2017, filed 14 Feb 2018.